CD11b Expression and Its Association with Clinical Biochemical Parameters in Patients with Acute Myeloid Leukemia

Abstract

Objective: Acute myeloid leukemia (AML) is a hematological malignancy characterized by marked clinical and biological heterogeneity, resulting in variable prognosis. Immunophenotypic markers have gained increasing importance in predicting disease outcome and guiding clinical management. This study aimed to evaluate the prognostic significance of CD11b expression and its association with biochemical, hematological, and coagulation parameters in adult patients diagnosed with AML. Methods: This retrospective observational study included 50 adult patients aged between 18 and 75 years who were diagnosed with AML between 2019 and 2023. Demographic data, complete blood count, biochemical and coagulation parameters, and CD11b expression levels measured by flow cytometry at diagnosis were analyzed. In our study, our patients were grouped into two separate categories. The first grouping consisted of 5 subgroups, while the second grouping consisted of 2 subgroups. Statistical analyses were performed to assess the relationship between CD11b expression and laboratory parameters. Results: In our study revealed significant differences in WBC levels between group. One of the striking findings of our study is the relationship between CD11b expression levels and serum creatinine levels. There was a significant difference in prothrombin time (PT) was found between the groups Conclusion: CD11b expression may serve as an important prognostic immunophenotypic marker in patients with AML. Its significant association with biochemical and coagulation parameters suggests that CD11b could contribute to risk stratification and clinical decision-making processes in AML management.

Keywords

• Acute myeloid leukemia
• CD11b
• biochemical parameters
• flow cytometry

Ethical Statement

SANKO University Non-Interventional Clinical Research Ethics Committee (Date: 14.10.2024, Number: 2024-10)

Thanks

This study was developed from Kevser Gülcan Yıldız’s master thesis 2025.

Akut Miyeloid Lösemi Hastalarında CD11b Ekspresyonunun Prognostik Önemi ve Klinik Biyokimyasal Parametrelerle İlişkisi

Abstract

Amaç: Akut miyeloid lösemi (AML), belirgin klinik ve biyolojik heterojenite ile karakterize edilen ve değişken prognoza yol açan bir hematolojik malignitedir. İmmünofenotipik belirteçler, hastalık sonucunu tahmin etmede ve klinik yönetimi yönlendirmede giderek daha önemli hale gelmiştir. Bu çalışma, AML tanısı konmuş yetişkin hastalarda CD11b ekspresyonunun prognostik önemini ve biyokimyasal, hematolojik ve koagülasyon parametreleriyle olan ilişkisini değerlendirmeyi amaçlamıştır. Yöntem: Bu retrospektif gözlemsel çalışmaya, 2019 ile 2023 yılları arasında AML tanısı konmuş 18 ile 75 yaş arası 50 yetişkin hasta dahil edilmiştir. Demografik veriler, tam kan sayımı, biyokimyasal ve koagülasyon parametreleri ve tanı anında akış sitometrisi ile ölçülen CD11b ekspresyon düzeyleri analiz edilmiştir. Çalışmamızda hastalarımız iki ayrı kategoriye ayrılmıştır. Birinci grup 5 alt gruptan, ikinci grup ise 2 alt gruptan oluşmuştur. CD11b ekspresyonu ile laboratuvar parametreleri arasındaki ilişkiyi değerlendirmek için istatistiksel analizler yapılmıştır. Bulgular: Çalışmamızda gruplar arasında beyaz kan hücresi (WBC) düzeylerinde anlamlı farklılıklar ortaya çıktı. Çalışmamızın dikkat çekici bulgularından biri, CD11b ekspresyon düzeyleri ile serum kreatinin düzeyleri arasındaki ilişkidir. Gruplar arasında protrombin zamanında (PT) anlamlı bir fark bulundu. Sonuç: CD11b ekspresyonu, AML hastalarında önemli bir prognostik immünofenotipik belirteç olarak işlev görebilir. Biyokimyasal ve pıhtılaşma parametreleriyle olan anlamlı ilişkisi, CD11b'nin AML yönetiminde risk sınıflandırmasına ve klinik karar verme süreçlerine katkıda bulunabileceğini düşündürmektedir.

Keywords

• Akut Miyeloid Lösemi
• CD11b
• Biyokimyasal parametreler
• Flow sitometri

Ethical Statement

SANKO Üniversitesi Girişimsel Olmayan Klinik Araştırma Etik Kurulu (Tarih: 14.10.2024, Numara: 2024-10)

Thanks

Bu çalışma, Kevser Gülcan Yıldız'ın 2025 tarihli yüksek lisans tezinden geliştirilmiştir.

References

1. 1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. New England Journal of Medicine. 2015;373(12):1136-52.
2. 2. Nix NM, Price A. Acute myeloid leukemia: an ever-changing disease. Journal of the Advanced Practitioner in Oncology. 2019;10(Suppl 4):4.
3. 3. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik V, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. New England Journal of Medicine. 2016;374(23):2209-21.
4. 4. Creutzig U, Zimmermann M, Bourquin J, et al. Favorable outcome in infants with AML after intensive first-and second-line treatment: an AML-BFM study group report. Leukemia. 2012;26(4):654-61.
5. 5. Basharat M, Khan SA, Din NU, Ahmed D. Immunophenotypic characterisation of morphologically diagnosed cases of Acute Myeloid Leukaemia (AML). Pak J Med Sci. 2019;35(2):470–476.
6. 6. Yan H, Qu J, Cao W, Liu Y, Zheng E, Cai Z. Identification of prognostic genes in the acute myeloid leukemia immune microenvironment based on TCGA data analysis. Cancer Immunol Immunother. 2019;68(12):1971-1978.
7. 7. Xu S, Li X, Zhang J, Jieping C. Prognostic Value of CD11b Expression Level for Acute Myeloid Leukemia Patients: A Meta-Analysis. PLoS One. 2015;10(8):e0135981.
8. 8. Huber S, Baer C, Hutter S, Dicker F, Meggendorfer M, Phlkamp C, et al. AML classification in the year 2023: How to avoid a Babylonian confusion of languages. Leukemia. 2023;37(7):1413-1420.

9. 9. Wysota M, Konopleva M, Mitchell S.Novel Therapeutic Targets in Acute Myeloid Leukemia (AML). Curr Oncol Rep. 2024;26(4):409-420.
10. 10. Cooper J, Giancotti FG. Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance. Cancer Cell. 2019;35(3):347–367.
11. 11. M. Baysal. CD11b Expression in Acute Myeloid Leukemia is Associated with Hemostatic Complications and Response to Treatment. NKMJ. 2020;8(1):621.
12. 12. Panni RZ , Herndon JM, Zuo C, Hedge S, Hogg GD, Knolhoff BL, et al. Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies. Sci Transl Med. 2019;11(499):eaau9240.
13. 13. Ahn G-O, Tseng D, Liao C-H, Dorie MJ, Czechowicz A, Brown JM. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc Natl Acad Sci U S A. 2010;107(18):8363-8.
14. 14. Cheng X, Wang H, Wang Z, Zhu B, Long H. Tumor-associated myeloid cells in cancer immunotherapy. J Hematol Oncol. 2023;16:71.
15. 15. Lundahl E. Alterations in adhesion molecule (CD11b/CD18 and CD62L) expression on granulocytes after chemotherapy. European Journal of Clinical Investigation. 2001;28(11):924-929.
16. 16. Schmid MC, Khan SQ, Kaneda MM, Pathria P, Shepard R, Louis TL. et al. Integrin CD11b activation drives anti-tumor innate immunity. Nat Commun. 2018;9:5379.
17. 17. Fjaertoft G, Håkansson LD, Pauksens K, Sisask G, Venge P. Neutrophil CD64 (FcgammaRI) expression is a specific marker of bacterial infection: a study on the kinetics and the impact of major surgery. Scand J Infect Dis. 2007;39(6-7):525-535.
18. 18. Xu S, Li X, Zhang J, Chen J. Prognostic Value of CD11b Expression Level for Acute Myeloid Leukemia Patients: A Meta-Analysis. Plos One. 2015;10(8): e0135981.
19. 19. Terregino CA, Lubkin CL, Thom SR. Impaired Neutrophil Adherence as an Early Marker of Systemic Inflammatory Response Syndrome and Severe Sepsis. Annals of Emergency Medicine. 1997;29(3):400-403.
20. 20. Chen J, Namiki S, Toma-Hirano M, Miyatake S, Ishida K, Shibata Y, et al. The role of CD11b in phagocytosis and dendritic cell development. Immunology Letters 2008;30;120(1-2):42-48.
21. 21. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844-54.
22. 22. Luciano RL, Brewster UC. Kidney involvement in leukemia and lymphoma. Adv Chronic Kidney Dis. 2014;21(1):2735.
23. 23. Libourel EJ, Klerk CPW, Norden YV, Maat MPM, Kruip MJ, et al. Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia. Blood. 2016;128(14):1854-1861.
24. 24. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111 (5): 2505–2515.
25. 25. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. Journal Thrombosis and Haemostasis. 2007;5(3):632-634.
26. 26. Dixit A, Chatterjee T, Mishra P, Saxene R, Choudhry VP. Clinical and Applied Thrombosis/Hemostasis. Clinical and Applied Trombosis/Hemotasis 2007;13(3):292-298.